SHILPAMED Shilpa Medicare Ltd US FDA Inspections Announcement 2025 - USFDA EIR Received Shilpa Pharma Lifesciences Limited, a subsidiary of Shilpa Medicare Ltd, received an Establishment Inspection Report (EIR) from the USFDA, classifying the site as Voluntary Action Indicated (VAI) after an inspection conducted from March 3-7, 2025..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Shilpa Medicare Ltd